source
- BioNTech's CTLA-4 antibody gotistobart shows 8.5-month survival boost in previously treated lung cancer patientsBioNTech reported new data on its CTLA-4 targeting antibody gotistobart in lung cancer. The study focused on patients whose disease had progressed after prior therapy. Those receiving gotistobart…
- FDA holds hearing on access and safety as psychedelic drug approval loomsThe Food and Drug Administration convened a public hearing to collect input on how emerging psychedelic medicines should be used, monitored, and continuously studied as a potential first approval a…